#Bristol Myers Squibb

Advocates claim Gilead and others unfairly limited competition for HIV combination pills.

Class action lawsuit challenges deals that limit generic drug competition; Gilead says the case is without merit.

Pharma giants made agreements to keep prices high and block competition for generics, the civil lawsuit alleges.

Stop me if you’ve heard this one before.

Who are the top 20 funders across the globe? This annual FCAA report lists them all.

The company is losing its exclusive rights to two HIV drugs: Reyataz and Sustiva.

ViiV Healthcare recently acquired Bristol-Myers Squibb’s (BMS) portfolio of HIV antiretrovirals (ARVs) in the pipeline.

The sale includes an HIV attachment inhibitor called fostemsavir and a maturation inhibitor, both in late-stage development.

A placebo-controlled Phase IIa study of BMS-955176 has shown that the experimental ARV is potent, safe and well-tolerated.

Here’s what’s in store this year for new hepatitis C therapies, as well as approvals for new uses of existing treatments.

ViiV Healthcare has announced plans to acquire the portfolio of HIV antiretrovirals Bristol-Myers Squibb has in development.